Digest Network Come funziona
Network
/
Società
Mo
Non verificato

MoonLake Immunotherapeutics AG

Di cosa scriviamo

Annunci EconomiciBiotecnologiaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

18 comunicati stampa

Guarda tutti i comunicati
10/08/2026
Biotecnologia
Annunci Economici
Management/Organizzazione Aziendale
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
21/06/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
10/05/2026
Biotecnologia
Annunci Economici
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
28/03/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
22/02/2026
Biotecnologia
Annunci Economici
Medicina Salute Benessere
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
02/02/2026
Biotecnologia
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
08/01/2026
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
05/11/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
05/11/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
28/09/2025
Biotecnologia
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
Fonte
MoonLake Immunotherapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0